Research Watch, Arthritis Drugs, May 2007

1

ARTICLE: 'Cardiovascular Outcomes in High-Risk Patients with Osteoarthritis Treated with Ibuprofen, Naproxen, or Lumiracoxib'

JOURNAL: Annals of the Rheumatic Diseases 2007 Apr 5; [Epub ahead of print]

SUMMARY: The Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) of 18,325 osteoarthritis patients comprised two parallel sub-studies, comparing lumiracoxib to either ibuprofen or naproxen. In high cardiovascular risk patients among aspirin users, patients in the ibuprofen sub-study had more primary events with ibuprofen than lumiracoxib, whereas in the naproxen sub-study rates were similar for naproxen and lumiracoxib. High-risk patients not taking aspirin had fewer primary events with naproxen …